Sitagliptin / Metformin hydrochloride Accord Umoja wa Ulaya - Kipolandi - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. potrójnej terapii skojarzonej), jako uzupełnienie diety i ćwiczeń fizycznych u pacjentów niedostatecznie kontrolowanych o ich maksymalnej tolerowanej dawki sulfonylomocznika z metforminą i. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Dabigatran Etexilate Accord Umoja wa Ulaya - Kipolandi - EMA (European Medicines Agency)

dabigatran etexilate accord

accord healthcare s.l.u. - za pomocą dabigatran mesylate - venous thromboembolism; arthroplasty, replacement - Środki przeciwzakrzepowe - prevention of venous thromboembolic events.

Tolvaptan Accord Umoja wa Ulaya - Kipolandi - EMA (European Medicines Agency)

tolvaptan accord

accord healthcare s.l.u. - Толваптан - niewłaściwy zespół adh - leki moczopędne, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).